Raras
Buscar doenças, sintomas, genes...
Porfiria aguda intermitente
ORPHA:79276CID-10 · E80.2CID-11 · 5C58.1YOMIM 176000PCDT · SUSDOENÇA RARA

A porfiria intermitente aguda é a forma mais comum e mais grave das porfirias hepáticas agudas. Ela é caracterizada pelo aparecimento de crises que atingem os nervos e órgãos internos, sem manifestações na pele.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

A porfiria intermitente aguda é a forma mais comum e mais grave das porfirias hepáticas agudas. Ela é caracterizada pelo aparecimento de crises que atingem os nervos e órgãos internos, sem manifestações na pele.

Pesquisas ativas
5 ensaios
22 total registrados no ClinicalTrials.gov
Publicações científicas
1.942 artigos
Último publicado: 2026 Apr 6

Escala de raridade

CLASSIFICAÇÃO ORPHANET · BRASIL 2024
1-9 / 1 000 000
Ultra-rara
<1/50k
Muito rara
1/20k
Rara
1/10k
Pouco freq.
1/5k
Incomum
1/2k
Prevalência
0.54
Europe
Início
Adolescent
+ adult
🏥
SUS: Cobertura parcialScore: 50%
PCDT disponívelCentros em: PA, PR, SC, RS, ES +8CID-10: E80.2
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🧠
Neurológico
11 sintomas
🫃
Digestivo
8 sintomas
🫘
Rins
6 sintomas
💪
Músculos
5 sintomas
🫁
Pulmão
2 sintomas
🦴
Ossos e articulações
1 sintomas

+ 26 sintomas em outras categorias

Características mais comuns

90%prev.
Porfirinúria
Muito frequente (99-80%)
90%prev.
Atividade anormal de enzima/coenzima
Muito frequente (99-80%)
90%prev.
Dor abdominal
Muito frequente (99-80%)
90%prev.
Aumento do porfobilinogênio urinário
Muito frequente (99-80%)
90%prev.
Ácido delta-aminolevulínico urinário elevado
Muito frequente (99-80%)
55%prev.
Dor em membro
Frequente (79-30%)
61sintomas
Muito frequente (5)
Frequente (11)
Ocasional (28)
Muito raro (7)
Sem dados (10)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 61 características clínicas mais associadas, ordenadas por frequência.

PorfirinúriaPorphyrinuria
Muito frequente (99-80%)90%
Atividade anormal de enzima/coenzimaAbnormal enzyme/coenzyme activity
Muito frequente (99-80%)90%
Dor abdominalAbdominal pain
Muito frequente (99-80%)90%
Aumento do porfobilinogênio urinárioIncreased urinary porphobilinogen
Muito frequente (99-80%)90%
Ácido delta-aminolevulínico urinário elevadoElevated urinary delta-aminolevulinic acid
Muito frequente (99-80%)90%

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico1.942PubMed
Últimos 10 anos200publicações
Pico202360 papers
Linha do tempo
2026Hoje · 2026🧪 1993Primeiro ensaio clínico📈 2023Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

1 gene identificado com associação a esta condição. Padrão de herança: Autosomal dominant.

HMBSPorphobilinogen deaminaseDisease-causing germline mutation(s) inRestrito
FUNÇÃO

As part of the heme biosynthetic pathway, catalyzes the sequential polymerization of four molecules of porphobilinogen to form hydroxymethylbilane, also known as preuroporphyrinogen (PubMed:18004775, PubMed:18936296, PubMed:19138865, PubMed:23815679). Catalysis begins with the assembly of the dipyrromethane cofactor by the apoenzyme from two molecules of porphobilinogen or from preuroporphyrinogen. The covalently linked cofactor acts as a primer, around which the tetrapyrrole product is assemble

LOCALIZAÇÃO

Cytoplasm, cytosol

VIAS BIOLÓGICAS (1)
Heme biosynthesis
MECANISMO DE DOENÇA

Acute intermittent porphyria

A form of porphyria. Porphyrias are inherited defects in the biosynthesis of heme, resulting in the accumulation and increased excretion of porphyrins or porphyrin precursors. They are classified as erythropoietic or hepatic, depending on whether the enzyme deficiency occurs in red blood cells or in the liver. AIP is an autosomal dominant form of hepatic porphyria characterized by attacks of gastrointestinal disturbances, abdominal colic, with neurological dysfunctions, hypertension, tachycardia and peripheral neuropathy. Most attacks are precipitated by drugs, alcohol, caloric deprivation, infections, or endocrine factors.

VIAS REACTOME (1)
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
26.1 TPM
Fibroblastos
22.1 TPM
Sangue
15.6 TPM
Baço
15.2 TPM
Tireoide
14.1 TPM
OUTRAS DOENÇAS (3)
leukoencephalopathy, porphyria-relatedacute intermittent porphyriaencephalopathy, porphyria-related
HGNC:4982UniProt:P08397

Medicamentos aprovados (FDA)

1 medicamento encontrado nos registros da FDA americana.

💊 Chlorpromazine Hydrochloride (CHLORPROMAZINE HYDROCHLORIDE)
Ver no DailyMed/FDA

Variantes genéticas (ClinVar)

300 variantes patogênicas registradas no ClinVar.

🧬 HMBS: NM_000190.4(HMBS):c.633dup (p.Met212fs) ()
🧬 HMBS: NM_000190.4(HMBS):c.143del (p.Gly48fs) ()
🧬 HMBS: NM_000190.4(HMBS):c.652-1G>A ()
🧬 HMBS: NM_000190.4(HMBS):c.912+1G>T ()
🧬 HMBS: NM_000190.4(HMBS):c.723del (p.Glu242fs) ()
Ver todas no ClinVar

Classificação de variantes (ClinVar)

Distribuição de 141 variantes classificadas pelo ClinVar.

106
35
Patogênica (75.2%)
VUS (24.8%)
VARIANTES MAIS SIGNIFICATIVAS
HMBS: NM_000190.4(HMBS):c.33+1G>C [Pathogenic]
HMBS: NM_000190.4(HMBS):c.160_160+1del [Pathogenic]
HMBS: NM_000190.4(HMBS):c.760del (p.Phe253_Leu254insTer) [Pathogenic]
HMBS: NM_000190.4(HMBS):c.9_33+11del [Pathogenic]
HMBS: NM_000190.4(HMBS):c.772-2A>G [Pathogenic]

Vias biológicas (Reactome)

1 via biológica associada aos genes desta condição.

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
3Fase 32
2Fase 25
1Fase 14
·Pré-clínico9
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Porfiria aguda intermitente

Centros de Referência SUS

21 centros habilitados pelo SUS para Porfiria aguda intermitente

Centros para Porfiria aguda intermitente

Detalhes dos centros

Hospital Universitário Prof. Edgard Santos (HUPES)

R. Dr. Augusto Viana, s/n - Canela, Salvador - BA, 40110-060 · CNES 0003808

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Apoio de Brasília (HAB)

AENW 3 Lote A Setor Noroeste - Plano Piloto, Brasília - DF, 70684-831 · CNES 0010456

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Estadual Infantil e Maternidade Alzir Bernardino Alves (HIABA)

Av. Min. Salgado Filho, 918 - Soteco, Vila Velha - ES, 29106-010 · CNES 6631207

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital das Clínicas da UFG

Rua 235 QD. 68 Lote Área, Nº 285, s/nº - Setor Leste Universitário, Goiânia - GO, 74605-050 · CNES 2338424

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da UFMG

Av. Prof. Alfredo Balena, 110 - Santa Efigênia, Belo Horizonte - MG, 30130-100 · CNES 2280167

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

NUPAD / Faculdade de Medicina UFMG

Av. Prof. Alfredo Balena, 189 - 5 andar - Centro, Belo Horizonte - MG, 30130-100 · CNES 2183226

Serviço de Referência

Rota
Erros Inatos do Metabolismo

Hospital Universitário João de Barros Barreto

R. dos Mundurucus, 4487 - Guamá, Belém - PA, 66073-000 · CNES 2337878

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da Universidade Federal de Pernambuco

Av. Prof. Moraes Rego, 1235 - Cidade Universitária, Recife - PE, 50670-901 · CNES 2561492

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Instituto de Medicina Integral Prof. Fernando Figueira (IMIP)

R. dos Coelhos, 300 - Boa Vista, Recife - PE, 50070-902 · CNES 0000647

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UFPR

R. Gen. Carneiro, 181 - Alto da Glória, Curitiba - PR, 80060-900 · CNES 2364980

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Pedro Ernesto (HUPE-UERJ)

Blvd. 28 de Setembro, 77 - Vila Isabel, Rio de Janeiro - RJ, 20551-030 · CNES 2280221

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Instituto Nacional de Saúde da Mulher, da Criança e do Adolescente Fernandes Figueira (IFF/Fiocruz)

Av. Rui Barbosa, 716 - Flamengo, Rio de Janeiro - RJ, 22250-020 · CNES 2269988

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário Onofre Lopes (HUOL)

Av. Nilo Peçanha, 620 - Petrópolis, Natal - RN, 59012-300 · CNES 2408570

Atenção Especializada

Rota
Erros Inatos do Metabolismo

Hospital São Lucas da PUCRS

Av. Ipiranga, 6690 - Jardim Botânico, Porto Alegre - RS, 90610-000 · CNES 2232928

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital de Clínicas de Porto Alegre (HCPA)

Rua Ramiro Barcelos, 2350 Bloco A - Av. Protásio Alves, 211 - Bloco B e C - Santa Cecília, Porto Alegre - RS, 90035-903 · CNES 2237601

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital Universitário da UFSC (HU-UFSC)

R. Profa. Maria Flora Pausewang - Trindade, Florianópolis - SC, 88036-800 · CNES 2560356

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo

Hospital das Clínicas da FMUSP

R. Dr. Ovídio Pires de Campos, 225 - Cerqueira César, São Paulo - SP, 05403-010 · CNES 2077485

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas da UNICAMP

R. Vital Brasil, 251 - Cidade Universitária, Campinas - SP, 13083-888 · CNES 2748223

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Hospital de Clínicas de Ribeirão Preto (HCRP-USP)

R. Ten. Catão Roxo, 3900 - Vila Monte Alegre, Ribeirão Preto - SP, 14015-010 · CNES 2082187

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do MetabolismoDeficiência Intelectual

Instituto da Criança e do Adolescente (ICr-HCFMUSP)

Av. Dr. Enéas Carvalho de Aguiar, 647 - Cerqueira César, São Paulo - SP, 05403-000 · CNES 2081695

Serviço de Referência

Rota
Erros Inatos do Metabolismo

UNIFESP / Hospital São Paulo

R. Napoleão de Barros, 715 - Vila Clementino, São Paulo - SP, 04024-002 · CNES 2688689

Serviço de Referência

Rota
Anomalias CongênitasErros Inatos do Metabolismo
Sobre os centros SUS: Estes centros são habilitados pelo Ministério da Saúde como Serviços de Referência em Doenças Raras ou Serviços de Atenção Especializada. O atendimento é pelo SUS, com encaminhamento da rede de atenção básica.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

3 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

22 ensaios clínicos encontrados, 5 ativos.

Distribuição por fase
NCT02935400 · Acute Porphyria Biomarkers for Disease ActivityAtivo
NCT01617642 · Dental Health, Diet, Inflammation and Biomarkers in Patients…Ativo
NCT02922413 · Panhematin for Prevention of Acute Attacks of PorphyriaEncerrado
PHASE2
NCT02180412 · Controlled Trial of Panhematin in Treatment of Acute Attacks…Concluído
PHASE2
NCT04056481 · Expanded Access Protocol of Givosiran for Patients With Acut…APPROVED_FOR_MARKETING
NCT03338816 · ENVISION: A Study to Evaluate the Efficacy and Safety of Giv…Concluído
PHASE3
NCT02949830 · A Study to Evaluate Long-term Safety and Clinical Activity o…Concluído
PHASE1, PHASE2
NCT01568554 · Clinical Diagnosis of Acute PorphyriaConcluído
NCT03505853 · A Study to Investigate the Interaction Between Givosiran and…Concluído
PHASE1
NCT03547297 · INSIGHT-AHP: A Study to Characterize the Prevalence of Acute…Encerrado
NCT02452372 · A Phase 1 Study of Givosiran (ALN-AS1) in Patients With Acut…Concluído
PHASE1
NCT00418795 · Porphozym in the Treatment of Acute Attacks in AIPConcluído
PHASE2, PHASE3
NCT02943213 · Assessment of Intra-subject Variability in the Bioavailabili…Concluído
PHASE1
NCT02082860 · Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5…Concluído
PHASE1
NCT02076763 · Observational Study of Acute Intermittent Porphyria PatientsConcluído
NCT00004789 · Phase I/II Study of Heme Arginate and Tin Mesoporphyrin for …Concluído
PHASE1, PHASE2
NCT00004396 · Studies in Porphyria III: Heme and Tin Mesoporphyrin in Acut…Concluído
PHASE2
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

🥈Melhor nível de evidência: Observacional
Timeline de publicações
474 papers (10 anos)
#1

The Case of a 37-Year-Old Woman Presenting With Subacute Weakness and Paresthesias.

Annals of clinical and translational neurology2026 Mar

Acute intermittent porphyria (AIP) is a rare metabolic disorder that may present with subacute neuropathy and systemic symptoms, often leading to diagnostic delay. We report a 37-year-old woman with eight weeks of progressive bilateral upper extremity weakness and paresthesias, followed by lower extremity involvement and falls, in the setting of chronic abdominal pain, presyncope, weight loss, and neuropsychiatric symptoms. Examination revealed profound proximal arm weakness, sensory deficits, bulbar involvement, and autonomic features. MRI of the brain and spine and cerebrospinal fluid analysis were normal. Electrodiagnostic studies demonstrated a severe diffuse motor neurogenic process. Markedly elevated urinary porphobilinogen and aminolevulinic acid levels confirmed the diagnosis of acute intermittent porphyric neuropathy, supported by identification of a variant of uncertain significance in the HMBS gene. This case underscores the importance of considering AIP in patients with subacute motor-predominant neuropathy accompanied by abdominal pain and autonomic dysfunction, as early diagnosis enables timely treatment and improved outcomes.

#2

Biallelic pathogenic hydroxymethylbilane synthase gene variants of a neurodegenerative disorder with progressive cystic leukoencephalopathy: a case report.

Journal of medical case reports2026 Feb 23

Heterozygous mutations of the hydroxymethylbilane synthase gene can lead to acute intermittent porphyria, with episodic abdominal pain and neuropsychiatric symptoms. The heme precursors 5-aminolevulinic acid and porphobilinogen accumulate due to enzyme deficiency. Case reports of biallelic pathogenic hydroxymethylbilane synthase gene variants are very rare. This case report presents a severely affected boy with biallelic pathogenic hydroxymethylbilane synthase gene variants and includes literature overview of other case reports and experimental data. At the age of 2 years, a Caucasian boy with pathologic psychomotor development was diagnosed with biallelic pathogenic hydroxymethylbilane synthase gene variants. As in previous case reports, he did not exhibit symptoms of acute intermittent porphyria, but progressive cystic leukoencephalopathy and neurological decay. In his urine, 5-aminolevulinic acid and porphobilinogen were markedly elevated, but in cerebrospinal fluid just porphobilinogen. Data of human and animal studies indicate that neurologic symptoms of acute intermittent porphyria are caused by 5-aminolevulinic acid, which episodically accumulates from hepatic origin. Here, as long-term treatment, the inhibition of hepatic heme synthesis with the small interfering RNA givosiran has proven to be effective. In case of biallelic pathogenic hydroxymethylbilane synthase gene variants, the heme precursors 5-aminolevulinic acid or porphobilinogen originating from the liver or central nervous system could be causative, and absolute heme deficiency in the central nervous system is another hypothesis. However, parenterally administered heme, which is effective in acute intermittent porphyria, does not reach the central nervous system. In one case of biallelic pathogenic hydroxymethylbilane synthase gene variants, a liver transplantation did not lead to long-term benefit. For differential diagnosis of cystic leukoencephalopathy, biallelic pathogenic hydroxymethylbilane synthase gene variants should be considered. Its pathogenesis probably differentiates from acute intermittent porphyria. To date, there is no promising therapeutic approach.

#3

Liver Transplantation and Other Hepatically Directed Therapies Do Not Change the Biochemical Phenotype nor Halt Progression of Leukodystrophy due to Biallelic HMBS Variants: A Case Report.

JIMD reports2026 Jan

Leukodystrophy due to biallelic HMBS variants is a rare condition distinct from acute intermittent porphyria (AIP). It is characterised by progressive leukoencephalopathy rather than acute attacks of neurovisceral symptoms. We report the ongoing clinical progression of a patient with leukodystrophy due to homozygous variants in HMBS [c.251C>A, p.Ala84Asp] despite liver transplantation. We demonstrate that porphyrin precursor levels are unchanged following liver transplantation in the periphery and that porphyrin precursor levels are constitutively elevated in the cerebrospinal fluid and are not reduced by haem arginate therapy. Liver transplantation and hepatically directed therapies are not likely to be effective for leukodystrophy due to biallelic HMBS variants. Alternative treatment strategies should be developed for effective management of this disorder. One-liner: Leukodystrophy due to biallelic HMBS variants is unlikely to be cured by liver transplantation or other hepatically directed therapies.

#4

Tolvaptan: a potential rescue therapy for SIADH with refractory hyponatremia associated with acute intermittent porphyria.

Journal of pediatric endocrinology &amp; metabolism : JPEM2026 Mar 26
#5

Porphyrias: Pathophysiology and clinical management recommendations for hepatologists.

Hepatology communications2025 Dec 01

In humans, an enzyme dysfunction in heme biosynthesis results in a heterogenous group of diseases collectively known as porphyrias. From a clinical standpoint, porphyrias can be classified as erythropoietic (congenital erythropoietic porphyria-CEP, erythropoietic/X-linked protoporphyria-EPP/XLP) or hepatic (acute hepatic porphyrias-AHPs, porphyria cutanea tarda-PCT), according to the site of organ dysfunction deemed to be responsible for the disease. In terms of total heme production, the liver accounts for the second major heme-synthesizing organ, after the bone marrow. In fact, heme is necessary as a prosthetic group in countless biologic functions, to which hepatic contribution is essential. Furthermore, the pathway of heme biosynthesis is inscribed into a network of fundamental metabolic reactions largely occurring in hepatocytes. Independent of their classification, all porphyrias share some degree of involvement of the liver, either in the pathogenesis, clinical manifestations, or as a preferential target of damage. Crucially, even those types of porphyrias that have been classically defined as erythropoietic do present a hepatic involvement, which can lead to poor clinical outcomes if neglected. Therefore, hepatologists should consider porphyrias as a differential diagnosis for otherwise unexplained presentations of liver disease. At the same time, a multidisciplinary team dealing with the diagnostic workup and clinical management of all types of porphyrias must include an expert in liver diseases. In this review, we aimed to recapitulate the main aspects of liver involvement in porphyrias, while also providing practical tools to recognize and manage these conditions from the hepatologist's perspective.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC1.409 artigos no totalmostrando 199

2026

Biallelic pathogenic hydroxymethylbilane synthase gene variants of a neurodegenerative disorder with progressive cystic leukoencephalopathy: a case report.

Journal of medical case reports
2026

Tolvaptan: a potential rescue therapy for SIADH with refractory hyponatremia associated with acute intermittent porphyria.

Journal of pediatric endocrinology &amp; metabolism : JPEM
2025

Claw hands in acute intermittent porphyria.

Oxford medical case reports
2025

Paraneoplastic hypoglycemia caused by hepatocarcinoma in a patient with acute intermittent porphyria.

Journal of gastrointestinal and liver diseases : JGLD
2026

The Case of a 37-Year-Old Woman Presenting With Subacute Weakness and Paresthesias.

Annals of clinical and translational neurology
2026

Liver Transplantation and Other Hepatically Directed Therapies Do Not Change the Biochemical Phenotype nor Halt Progression of Leukodystrophy due to Biallelic HMBS Variants: A Case Report.

JIMD reports
2025

A Curious Case of Abdominal Pain with Reset Osmostat and Rhabdomyolysis.

The Journal of the Association of Physicians of India
2025

Acute hepatic porphyrias.

Porto biomedical journal
2025

Acute Necrotizing Pancreatitis Secondary to Acute Intermittent Porphyria: A Rare Clinical Association.

ACG case reports journal
2025

Porphyrias: Pathophysiology and clinical management recommendations for hepatologists.

Hepatology communications
2025

Acute Intermittent Porphyria With Epilepsy as the Initial Symptom and Posterior Reversible Encephalopathy Syndrome: A Case Report.

Case reports in neurological medicine
2025

Acute Intermittent Porphyria: A Rare Cause of Postoperative Abdominal Pain and Hyponatremia.

Cureus
2025

Oral lipoteichoic and lipoic acids improve insulin resistance and body composition in porphyria mice on a high-carbohydrate diet.

Journal of physiology and biochemistry
2025

[Abdominal pain and severely impaired consciousness in a 19-year-old female patient].

Innere Medizin (Heidelberg, Germany)
2025

Managing Psychosis in Acute Intermittent Porphyria: A Case Report on Olanzapine Use.

Cureus
2025

An Adolescent Female With Disordered Eating and Cannabis Use Found to Have Acute Intermittent Porphyria.

Case reports in psychiatry
2025

Successful Pregnancy After Combined Liver and Renal Transplantation in a Patient With Acute Intermittent Porphyria.

Case reports in transplantation
2025

Clinical Features and Outcomes of Acute Intermittent Porphyria Presenting With Acute Quadriparesis: A Case Series and Follow-Up Study.

European journal of neurology
2025

A New Generation of Porphyrias: A Case of Acute Intermittent Porphyria.

Cureus
2025

Unmasked acute intermittent porphyria in a patient with COVID-19-associated posterior reversible encephalopathy syndrome.

BMC neurology
2025

Acute Hepatic Porphyria Presenting as Guillain-Barré Syndrome: Importance of Early Recognition and Screening.

The Neurohospitalist
2025

Unmasking Osmotic Demyelination Syndrome/Extrapontine Myelinolysis in Acute Intermittent Porphyria: Preventable Complications-Challenges in Diagnosis and Management.

Annals of Indian Academy of Neurology
2025

A novel HMBS gene mutation in acute intermittent porphyria: a case report of abdominal pain, seizures, and reversible neuroimaging findings.

Frontiers in genetics
2025

Nutrition and rare diseases: a case study of patients with acute intermittent porphyria (AIP).

Nutrition &amp; metabolism
2025

Acute hepatic porphyria in Denmark; a retrospective study.

Orphanet journal of rare diseases
2025

Practical Recommendations in the Treatment of Acute and Chronic Life-Threatening Infectious Diseases in Patients with Acute Hepatic Porphyria.

Metabolites
2025

A case report of acute intermittent porphyria presenting with reversible cerebral vasoconstriction syndrome.

Medicine
2025

Acute Hepatic Porphyria Should Be Included in the Diagnostic Work-Up of Patients with Resistant Hypertension or Suspected Secondary Hypertension.

Medical sciences (Basel, Switzerland)
2025

An easily overlooked disease in the early stages: acute intermittent porphyria.

BMC neurology
2025

Porphyric encephalopathy in a 15-year-old girl: A case report.

SAGE open medical case reports
2025

Specialty laboratory testing for chronic abdominal pain in irritable bowel syndrome.

Scandinavian journal of gastroenterology
2024

Diagnosing Porphyria in a Female Patient With Diffuse Pelvic Pain: A Case Study.

Cureus
2024

Acute Intermittent Porphyria in an Adolescent Patient: Diagnostic and Treatment Challenges.

Cureus
2024

Baseline urinary ALA and PBG as criteria for starting pharmacologic prophylactic treatment in acute intermittent porphyria treated with givosiran.

Molecular genetics and metabolism reports
2024

Givosiran: a targeted treatment for acute intermittent porphyria.

Hematology. American Society of Hematology. Education Program
2024

German Real-World Experience of Patients with Diverse Features of Acute Intermittent Porphyria Treated with Givosiran.

Journal of clinical medicine
2024

Worsening abdominal pain leading to false laparotomy: A case of acute intermittent porphyria.

JPMA. The Journal of the Pakistan Medical Association
2024

Effects of internet-based health education on patients with acute intermittent porphyria.

Orphanet journal of rare diseases
2024

Acute Intermittent Porphyria: A Diagnostic Conundrum.

Cureus
2025

Nontargeted urine metabolomic analysis of acute intermittent porphyria reveals novel interactions between bile acids and heme metabolism: New promising biomarkers for the long-term management of patients.

Journal of inherited metabolic disease
2024

Hepatocellular Carcinoma in Acute Hepatic Porphyria: A Meta-Analysis of Observational Studies.

Digestive diseases and sciences
2024

Hyponatremia associated with acute intermittent porphyria.

Kidney international
2024

Neuralgic amyotrophy presentation of acute intermittent porphyria: A case report.

Journal of the peripheral nervous system : JPNS
2024

Human Chorionic Gonadotropin (hCG) Injections Exacerbating Acute Intermittent Porphyria in a 34-Year-Old Woman.

Cureus
2024

Palliative Care Aspects of Acute Intermittent Porphyria - A Case Report.

Indian journal of palliative care
2025

Systemic messenger RNA replacement therapy is effective in a novel clinically relevant model of acute intermittent porphyria developed in non-human primates.

Gut
2024

Long-term follow-up of givosiran treatment in patients with acute intermittent porphyria from a phase 1/2, 48-month open-label extension study.

Orphanet journal of rare diseases
2024

Therapeutic approach to acute crises of hepatic porphyrias.

Revista clinica espanola
2024

Unraveling Complexity: Acute Intermittent Porphyria Complicated by Rhabdomyolysis and Acute Pancreatitis.

Cureus
2024

Acute intermittent porphyria: a disease with low penetrance and high heterogeneity.

Frontiers in genetics
2024

Givosiran for the Treatment of Pediatric Acute Intermittent Porphyria.

Journal of pediatric hematology/oncology
2024

Acute Intermittent Porphyria Presenting with Posterior Reversible Encephalopathy Syndrome, Reversible Cerebral Vasoconstriction Syndrome and Myocardial Ischemia: A Case Report and Review.

Psychology research and behavior management
2024

Cardiovascular abnormalities in patients with acute intermittent porphyria: the AIPRACUS study.

Polish archives of internal medicine
2024

Finding the Needle in a Haystack: Acute Intermittent Porphyria.

The American journal of medicine
2024

Effectiveness and tolerability of givosiran for the management of acute hepatic porphyria: A monocenter real-life evaluation.

Molecular genetics and metabolism reports
2024

Personalized pharmacological prophylaxis of acute intermittent porphyria: The need for objective biochemical markers.

Journal of hepatology
2024

Onset of Acute Intermittent Porphyria After Etonogestrel Implant Insertion: A Case Report.

Journal of pediatric hematology/oncology
2024

VS4 Nanodendrites with Narrow Bandgaps in Activating Dissolved Oxygen for Boosted Chemiluminescence and Hemin Detection by Unexpected Quenching.

Analytical chemistry
2024

Personalized dosage of Givosiran in acute intermittent porphyria.

Medicina clinica
2024

Long-term complications in acute porphyria.

Liver international : official journal of the International Association for the Study of the Liver
2024

Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs.

Seminars in liver disease
2024

Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report.

European review for medical and pharmacological sciences
2024

PICO questions and DELPHI methodology for improving the management of patients with acute hepatic porphyria.

Revista clinica espanola
2024

Kidney disease in acute intermittent porphyria: histological features and therapeutic perspectives.

Journal of nephrology
2024

An unexpected case of acute intermittent porphyria.

Acute medicine
2025

Case-based discussion of the acute hepatic porphyrias: Updates on pathogenesis, diagnosis and management.

Liver international : official journal of the International Association for the Study of the Liver
2024

Unveiling the Chameleon: A Case Report on Acute Intermittent Porphyria.

Cureus
2024

Preventing hyperhomocysteinemia using vitamin B6 supplementation in Givosiran-treated acute intermittent porphyria: Highlights from a case report and brief literature review.

Molecular genetics and metabolism reports
2024

Neurodevelopmental disorder in a patient with HMBS and SCN3A variants-A possibly blended phenotype further delineating autosomal recessive HMBS related disease.

American journal of medical genetics. Part A
2024

Xenobiotics Triggering Acute Intermittent Porphyria and Their Effect on Mouse Brain Respiratory Complexes.

Journal of xenobiotics
2024

Causal effect of porphyria biomarkers on alcohol-related hepatocellular carcinoma through Mendelian Randomization.

PloS one
2025

Liver transplantation and primary liver cancer in porphyria.

Liver international : official journal of the International Association for the Study of the Liver
2024

Use of Optical Coherence Tomography and Optical Coherence Tomography Angiography in the Diagnosis and Follow-Up of Endogenous Candida Endophthalmitis: A Case Report.

Medicina (Kaunas, Lithuania)
2023

Potential Biomarkers for the Earlier Diagnosis of Kidney and Liver Damage in Acute Intermittent Porphyria.

Life (Basel, Switzerland)
2023

A case report of acute intermittent porphyria leading to severe disability.

Frontiers in neurology
2023

Cimetidine Does Not Inhibit 5-Aminolevulinic Acid Synthase or Heme Oxygenase Activity: Implications for Treatment of Acute Intermittent Porphyria and Erythropoietic Protoporphyria.

Biomolecules
2024

Obstacles to Early Diagnosis of Acute Hepatic Porphyria: Current Perspectives on Improving Early Diagnosis and Clinical Management.

Clinical and experimental gastroenterology
2023

Functional and structural analysis of a novel splice site HMBS variant in a Chinese AIP patient.

Frontiers in genetics
2023

Acute Intermittent Porphyria Presenting with Non-Convulsive Status Epilepticus and Posterior Reversible Encephalopathy Syndrome.

Neurology India
2023

Clinical feature and genetic analysis of HMBS gene in Chinese patients with acute intermittent porphyria: a systematic review.

Frontiers in genetics
2023

The diagnosis of acute intermittent porphyria combined with seizures: Case report.

Medicine
2024

Treatment of Acute Intermittent Porphyria-Associated Anxiety Disorder With Gabapentin: Case Report and Review of Literature.

Journal of clinical psychopharmacology
2023

Acute Intermittent Porphyria Labeled Initially As Guillain-Barre Syndrome: Challenging Diagnosis.

Cureus
2023

Molecular analysis of eight splicing variants in the hydroxymethylbilane synthase gene.

Frontiers in genetics
2023

Clinical features of acute attacks, chronic symptoms, and long-term complications among patients with acute hepatic porphyria in Japan: a real-world claims database study.

Orphanet journal of rare diseases
2024

Premenstrual abdominal pain and posterior reversible encephalopathy syndrome in a woman with acute intermittent porphyria: A case report.

Asian journal of surgery
2023

Long-term management and treatment of acute intermittent porphyria with recurring attacks using pharmacological prophylaxis.

Hepatology communications
2023

Acute intermittent porphyria complicated with acute pancreatitis: A case report and literature review.

Medicine
2024

The Alpha-Lipoic Acid Improves Glucose Metabolism and Hyperinsulinemia in Acute Intermittent Porphyria: A Nutritional Concept for the Management of Rare Disorders.

Cellular and molecular gastroenterology and hepatology
2023

A novel mutation c.457C > T p.Q153 in the HMBS gene in a Mexican woman with acute intermittent porphyria.

Clinical case reports
2023

Acute Porphyria: An Unusual Case Of Quadriparesis, Hypertension, Recurrent Severe Cyclic Abdominal Pain, And Seizures.

JPMA. The Journal of the Pakistan Medical Association
2023

An Analysis and Literature Review of a Family Case of Acute Intermittent Porphyria With Initial Symptoms of Epileptic Seizure.

Cureus
2023

Needle in a Haystack: Acute Intermittent Porphyria, an Often-missed Differential Diagnosis of Abdominal Pain.

Journal of community hospital internal medicine perspectives
2024

One ring closer to a closure: the crystal structure of the ES3 hydroxymethylbilane synthase intermediate.

The FEBS journal
2023

Impact of acute hepatic porphyrias on the quality of life of patients according to the frequency of crises.

Medicina clinica
2023

Pathophysiology of attacks in acute hepatic porphyrias.

Medicina clinica
2023

HMBS gene mutations and hydroxymethylbilane synthase activity in acute intermittent porphyria: A systematic review.

Medicine
2023

Acute Intermittent Porphyria: A Review and Rehabilitation Perspective.

Cureus
2023

Mitochondrial DNA Copy Number Drives the Penetrance of Acute Intermittent Porphyria.

Life (Basel, Switzerland)
2023

First Report of a Low-Frequency Mosaic Mutation in the Hydroxymethylbilane Synthase Gene Causing Acute Intermittent Porphyria.

Life (Basel, Switzerland)
2023

Systematically testing human HMBS missense variants to reveal mechanism and pathogenic variation.

American journal of human genetics
2024

Acute Intermittent Porphyria in a Burn Patient: Case Study and Review of the Literature.

Journal of burn care &amp; research : official publication of the American Burn Association
2023

Reducing diagnostic delays in Acute Hepatic Porphyria using electronic health records data and machine learning: a multicenter development and validation study.

medRxiv : the preprint server for health sciences
2023

Porphyrin precursors and risk of primary liver cancer in acute intermittent porphyria: A case-control study of 188 patients.

Journal of inherited metabolic disease
2023

Genetic analysis of acute intermittent porphyria caused by novel classical splicing variant in the insertion region of 29-residue specific to human HMBS protein.

Frontiers in molecular biosciences
2023

Nutritional Interventions with Bacillus coagulans Improved Glucose Metabolism and Hyperinsulinemia in Mice with Acute Intermittent Porphyria.

International journal of molecular sciences
2024

Update on the Porphyrias.

Annual review of medicine
2023

Takotsubo Cardiomyopathy Triggered by Acute Intermittent Porphyria.

Cureus
2023

Status Epilepticus as a Presenting Feature in Posterior Reversible Encephalopathy Syndrome: Tertiary Care Center Experience.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
2023

Acute intermittent porphyria: Acute flare-up resolved with givosiran.

Medicina clinica
2023

Efficacy and safety of givosiran for acute hepatic porphyria: Final results of the randomized phase III ENVISION trial.

Journal of hepatology
2023

Evaluating the Efficacy of a Small Interfering Ribonucleic Acid Molecule, Givosiran, in Treating Acute Intermittent Porphyria: A Systematic Review.

Cureus
2023

Rare Coexistence of Acute Intermittent Porphyria With Systemic Lupus Erythematous: Case Report and Literature Review.

Journal of investigative medicine high impact case reports
2023

Detect Acute Porphyrias in Emergency Departments (DePorED) - a pilot study.

Orphanet journal of rare diseases
2023

[Abdominal pain with neuropsychiatric symptoms and ventilatory failure as a presentation of acute porphyria].

Revista medica del Instituto Mexicano del Seguro Social
2023

Intrahepatic Cholangiocarcinoma and Acute Intermittent Porphyria: A Case Report.

Journal of clinical medicine
2023

Acute Intermittent Porphyria Attack Triggered by COVID-19 Infection.

Cureus
2023

Porphyrias: Uncommon disorders masquerading as common childhood diseases.

Journal of postgraduate medicine
2023

Maternal and fetal outcomes in acute hepatic porphyria: A Swedish National Cohort Study.

Journal of inherited metabolic disease
2023

Key terms and definitions in acute porphyrias: Results of an international Delphi consensus led by the European porphyria network.

Journal of inherited metabolic disease
2023

Acute Intermittent Porphyria's Symptoms and Management: A Narrative Review.

Cureus
2023

A Case of Acute Intermittent Porphyria Leading to Severe Disability in a Young 21-Year-Old Female.

Cureus
2023

Acute intermittent porphyria: A rare cause of syndrome of inappropriate antidiuretic hormone secretion.

The journal of the Royal College of Physicians of Edinburgh
2023

Recurrent symptoms of acute intermittent porphyria after biochemical normalization with givosiran-An ongoing clinical conundrum.

JIMD reports
2023

[Research Progress in Pathogenesis of Hypertension in Acute Intermittent Porphyria].

Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae
2023

Transcriptome profile analysis reveals putative molecular mechanisms of 5-aminolevulinic acid toxicity.

Archives of biochemistry and biophysics
2023

A 25-Hour Fast Among Quiescent Hereditary Coproporphyria and Variegate Porphyria Patients is Associated With a Low Risk of Complications.

Rambam Maimonides medical journal
2023

AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.

Gastroenterology
2023

Transcriptomic study in explanted liver from a patient with acute intermittent porphyria.

JIMD reports
2023

Quantifying the impact of symptomatic acute hepatic porphyria on well-being via patient-reported outcomes: Results from the Porphyria Worldwide Patient Experience Research (POWER) study.

JIMD reports
2023

Clinical features of Japanese patients with acute hepatic porphyria.

JIMD reports
2022

Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria.

International journal of molecular sciences
2023

[Acute hepatic porphyrias].

Medizinische Klinik, Intensivmedizin und Notfallmedizin
2023

An Overview of Acute Hepatic Porphyrias: Clinical Implications, Diagnostic Approaches, and Management Strategies.

Turkish archives of pediatrics
2022

Novel Mutation of Hydroxymethylbilane Synthase in a Case of Acute Intermittent Porphyria Presenting with Posterior Reversible Encephalopathy Syndrome.

Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
2023

Idiosyncratic drug-induced liver injury caused by givosiran in a patient with acute intermittent porphyria.

Molecular genetics and metabolism reports
2022

Porphyria: a case report.

Journal of medical case reports
2022

Mortality in Pedigrees with Acute Intermittent Porphyria.

Life (Basel, Switzerland)
2023

Risk for incident comorbidities, nonhepatic cancer and mortality in acute hepatic porphyria: A matched cohort study in 1244 individuals.

Journal of inherited metabolic disease
2022

Novel hydroxymethylbilane synthase gene mutation identified and confirmed in a woman with acute intermittent porphyria: A case report.

World journal of clinical cases
2022

A Medical Conundrum in a Surgical Setting: Lessons Learned From an Atypical Case of Hyponatremia.

Cureus
2022

Recent Insights into the Pathogenesis of Acute Porphyria Attacks and Increasing Hepatic PBGD as an Etiological Treatment.

Life (Basel, Switzerland)
2022

Concomitant Presentation of Acute Acalculous Cholecystitis and Acute Colitis in a Patient with Behcet's Disease.

Cureus
2022

Acute Intermittent Porphyria as a Rare Challenging Neuro-Metabolic Disease; a Case Report.

Archives of academic emergency medicine
2023

Clinical-Pathological Conference Series from the Medical University of Graz : Case No 175: A 54-year-old man with hyponatremia and delirium after surgery for a prolapsed disc.

Wiener klinische Wochenschrift
2023

Acute intermittent porphyria presenting with first episode seizure and rhabdomyolysis.

Acta neurologica Belgica
2022

Acute Intermittent Porphyria: Complete Phenotype in a Patient with p.Arg173Trp Variant in Thailand.

The American journal of case reports
2022

A novel heterozygous mutation in the hydroxymethylbilane synthase gene in a case with acute intermittent porphyria.

Qatar medical journal
2022

Biomarkers that predict attacks of acute intermittent porphyria.

Translational gastroenterology and hepatology
2022

Reversible Cerebral Vasospasm in Acute Intermittent Porphyria: A Case Report and Review of the Literature.

European journal of case reports in internal medicine
2023

Heterogeneous molecular behavior in liver tumors (HCC and CCA) of two patients with acute intermittent porphyria.

Journal of cancer research and clinical oncology
2022

ALAD Inhibition by Porphobilinogen Rationalizes the Accumulation of δ-Aminolevulinate in Acute Porphyrias.

Biochemistry
2022

Long-term Remission of Acute Intermittent Porphyria Treated with Gonadotropin-Releasing Hormone Analogues and Estrogen: a Case Report.

Clinical laboratory
2022

Characterisation of a common hotspot variant in acute intermittent porphyria sheds light on the mechanism of hydroxymethylbilane synthase function.

FEBS open bio
2022

'Swollen heart' in the course of acute intermittent porphyria associated with severe hyponatraemia.

European heart journal. Cardiovascular Imaging
2022

Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases.

International review of cell and molecular biology
2022

Comments on "A Case of MELAS With the m.3243A>G Variant of the MT-TL1 Gene Mimicking Acute Intermittent Porphyria".

Journal of clinical neurology (Seoul, Korea)
2022

Re: Comments on "A Case of MELAS With the m.3243A>G Variant of the MT-TL1 Gene Mimicking Acute Intermittent Porphyria": The Authors Respond.

Journal of clinical neurology (Seoul, Korea)
2022

Development and validation of diagnostic algorithms for the laboratory diagnosis of porphyrias.

Journal of inherited metabolic disease
2022

Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.

Orphanet journal of rare diseases
2022

Dental and Periodontal Health in Acute Intermittent Porphyria.

Life (Basel, Switzerland)
2022

Case Report: Lack of Response to Givosiran in a Case of ALAD Porphyria.

Frontiers in genetics
2022

Organophosphate insecticide poisoning with monocrotophos-induced fabricated illness in a 7-year-old girl with refractory seizures over a 4-year period.

Paediatrics and international child health
2022

Hyperhomocysteinemia in acute hepatic porphyria (AHP) and implications for treatment with givosiran.

Expert review of gastroenterology &amp; hepatology
2022

Therapy Follows Diagnosis: Old and New Approaches for the Treatment of Acute Porphyrias, What We Know and What We Should Know.

Diagnostics (Basel, Switzerland)
2022

Porphyria-induced Postpartum Reversible Posterior Encephalopathy Syndrome.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
2022

Time is of the Essence: Using Extended Hemin Treatment for a Case of Severe Acute Intermittent Porphyria.

ACG case reports journal
2022

A Perfect Storm: Abdominal Pain and Ileus Explained by Acute Intermittent Porphyria Caused by Prehospitalization and Intrahospitalization Factors.

Journal of investigative medicine high impact case reports
2022

Risk of Hepatocellular Carcinoma in Patients with Porphyria: A Systematic Review.

Cancers
2022

Acute intermittent porphyria: prevalence of pathogenic HMBS variants in China, and epidemiological survey in Hebei Province, China.

Annals of translational medicine
2022

Neurological Manifestations of Acute Porphyrias.

Current neurology and neuroscience reports
2022

Bi-allelic hydroxymethylbilane synthase inactivation defines a homogenous clinico-molecular subtype of hepatocellular carcinoma.

Journal of hepatology
2022

A Case of MELAS With the m.3243A>G Variant of the MT-TL1 Gene Mimicking Acute Intermittent Porphyria.

Journal of clinical neurology (Seoul, Korea)
2022

Update on the diagnosis and management of the autosomal dominant acute hepatic porphyrias.

Journal of clinical pathology
2022

Acute intermittent porphyria: is oseltamivir safe in these patients?

Clinical medicine (London, England)
2022

Givosiran for the treatment of acute hepatic porphyria.

Expert review of clinical pharmacology
2022

Acute Intermittent Porphyria in Prepubertal Child-diagnostic and Therapeutic Challenges in India: A Case Report and Literature Review.

Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine
2023

Diagnosis of acute intermittent porphyria in emergency department.

QJM : monthly journal of the Association of Physicians
2022

Wood's lamp urinary examination in acute intermittent porphyria.

QJM : monthly journal of the Association of Physicians
2022

High penetrance, recurrent attacks and thrombus formation in a family with hereditary coproporphyria.

JIMD reports
2022

Clinical Challenges of Acute Porphyria in the Young Adult.

The Neurohospitalist
2022

Evaluation of Metabolic Changes in Acute Intermittent Porphyria Patients by Targeted Metabolomics.

International journal of molecular sciences
2022

Cutting-Edge Therapies and Novel Strategies for Acute Intermittent Porphyria: Step-by-Step towards the Solution.

Biomedicines
2022

Long-term follow-up of acute porphyria in female patients: Update of clinical outcome and life expectancy.

Molecular genetics and metabolism reports
2022

Mechanistic modelling of enzyme-restoration effects of new recombinant liver-targeted proteins in acute intermittent porphyria.

British journal of pharmacology
2022

[Laboratory diagnostics of acute porphyrias].

MMW Fortschritte der Medizin
2022

Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals.

Journal of internal medicine
2022

Diagnosis of acute intermittent porphyria in a renal transplant patient: A case report.

World journal of transplantation
2022

RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.

Journal of internal medicine
2022

Givosiran in acute intermittent porphyria: A personalized medicine approach.

Molecular genetics and metabolism
2022

Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria.

Science translational medicine
2021

Kidney Involvement in Acute Hepatic Porphyrias: Pathophysiology and Diagnostic Implications.

Diagnostics (Basel, Switzerland)
2021

Complex response to physiological and drug-induced hepatic heme demand in monoallelic ALAS1 mice.

Molecular genetics and metabolism reports
2021

[Van Gogh's Pathography and the Influence of Illness on Painting].

Brain and nerve = Shinkei kenkyu no shinpo
2021

The crystal structures of the enzyme hydroxymethylbilane synthase, also known as porphobilinogen deaminase.

Acta crystallographica. Section F, Structural biology communications
2022

ABCB6 polymorphisms are not overly represented in patients with porphyria.

Blood advances
2021

Prophylactic Heme Arginate Infusion for Acute Intermittent Porphyria.

Frontiers in pharmacology
2021

Profiling of Serum Metabolites of Acute Intermittent Porphyria and Asymptomatic HMBS Mutation Carriers.

Cells
2021

Two Novel Hydroxymethylbilane Synthase Splicing Mutations Predispose to Acute Intermittent Porphyria.

International journal of molecular sciences
Ver todos os 1.409 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Porfiria aguda intermitente.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Porfiria aguda intermitente

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. The Case of a 37-Year-Old Woman Presenting With Subacute Weakness and Paresthesias.
    Annals of clinical and translational neurology· 2026· PMID 41408674mais citado
  2. Biallelic pathogenic hydroxymethylbilane synthase gene variants of a neurodegenerative disorder with progressive cystic leukoencephalopathy: a case report.
    Journal of medical case reports· 2026· PMID 41731635mais citado
  3. Liver Transplantation and Other Hepatically Directed Therapies Do Not Change the Biochemical Phenotype nor Halt Progression of Leukodystrophy due to Biallelic HMBS Variants: A Case Report.
    JIMD reports· 2026· PMID 41377573mais citado
  4. Tolvaptan: a potential rescue therapy for SIADH with refractory hyponatremia associated with acute intermittent porphyria.
    Journal of pediatric endocrinology &amp; metabolism : JPEM· 2026· PMID 41566564mais citado
  5. Porphyrias: Pathophysiology and clinical management recommendations for hepatologists.
    Hepatology communications· 2025· PMID 41236019mais citado
  6. Acute intermittent porphyria presenting as posterior reversible encephalopathy syndrome: a case report.
    J Med Case Rep· 2026· PMID 41943033recente
  7. Claw hands in acute intermittent porphyria.
    Oxf Med Case Reports· 2025· PMID 41458287recente
  8. Paraneoplastic hypoglycemia caused by hepatocarcinoma in a patient with acute intermittent porphyria.
    J Gastrointestin Liver Dis· 2025· PMID 41453103recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:79276(Orphanet)
  2. OMIM OMIM:176000(OMIM)
  3. MONDO:0008294(MONDO)
  4. Porfiria Aguda Intermitente(PCDT · Ministério da Saúde)
  5. GARD:5732(GARD (NIH))
  6. Variantes catalogadas(ClinVar)
  7. Busca completa no PubMed(PubMed)
  8. Artigo Wikipedia(Wikipedia)
  9. Q424247(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Porfiria aguda intermitente
Compêndio · Raras BR

Porfiria aguda intermitente

ORPHA:79276 · MONDO:0008294
🇧🇷 Brasil SUS
Geral
Prevalência
1-9 / 1 000 000
Herança
Autosomal dominant
CID-10
E80.2 · Outras porfirias
CID-11
Ensaios
5 ativos
Início
Adolescent, Adult
Prevalência
0.54 (Europe)
MedGen
UMLS
C0162565
Repurposing
2 candidatos
chlorpromazinedopamine receptor antagonist
heminenzyme inducer
EuropePMC
Wikidata
Wikipedia
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades